Clinical Trials on Carcinoma, Non-Small-Cell Lung in Hong Kong

Total 474 results

Novartis Pharmaceuticals

Terminated

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Non-small Cell Lung Cancer

France, Spain, United States, Belgium, Netherlands, Canada, Italy, Singapore, Korea, Republic of, Czechia, Germany, Hong Kong
AVEO Pharmaceuticals, Inc.

Completed

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Lung Neoplasms | Respiratory Tract Neoplasms | Lung Cancer | Carcinoma, Non-Small Cell-Lung

Hong Kong, Korea, Republic of, Malaysia, Philippines, Singapore, Taiwan, Thailand
Gilead Sciences
Arcus Biosciences, Inc.

Recruiting

Study of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung)

Lung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
Chinese University of Hong Kong

Unknown

A Retrospective Study Investigating the Factors Related to Non-tuberculous Mycobacterial Pulmonary Disease in Hong Kong

Non-Tuberculous Mycobacterial Pneumonia

Hong Kong
Eli Lilly and Company

Completed

A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung

China, Taiwan, Australia, Korea, Republic of, Egypt, Romania, India, Turkey
Cullinan Therapeutics Inc.

Recruiting

A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer (REZILIENT1)

Non Small Cell Lung Cancer | EGFR Exon 20 Mutation

United States, Taiwan, Spain, Korea, Republic of, Japan, Singapore, Italy, Netherlands, Hong Kong
Astellas Pharma Inc

Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NSCLC | Non Small Cell Lung Cancer

United States, Canada, Korea, Republic of, Singapore, Thailand, Hong Kong
Chinese University of Hong Kong

Completed

The Effect of Andrographis Paniculata (AP) on Palliative Management of Advanced Esophageal Cancer (AP)

Squamous Cell Carcinoma of Esophagus

China
Chinese University of Hong Kong

Recruiting

Prevalence of Non-alcoholic Fatty Liver Disease Among Non-obese Obstructive Sleep Apnea by Using Transient Elastography

Sleep Apnea, Obstructive | Fatty Liver

Hong Kong
Rain Oncology Inc

Terminated

Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions (RAIN)

NSCLC Stage IIIB | NSCLC, Recurrent | NRG1 Fusion | EGFR Exon 20 Insertion Mutation | NSCLC, Stage IIIC | NSCLC, Stage IV | HER2-activating Mutation | ERBB Fusion

United States, Canada, Hong Kong
Chinese University of Hong Kong

Completed

Obstructive Sleep Apnoea and CPAP Treatment Response in Patients With Non-alcoholic Fatty Liver Disease

Obstructive Sleep Apnea | Non-alcoholic Fatty Liver Disease

Hong Kong
National Cancer Centre, Singapore
Singapore General Hospital

Recruiting

Molecular Profiling Project

Non-Small Cell Lung Cancer | Lung Cancer

Thailand, Singapore, Hong Kong, Brunei Darussalam, India, Malaysia
AstraZeneca

Completed

To Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC) (PIONEER)

Non Small Cell Lung Cancer

Vietnam, Philippines, China, Hong Kong, Taiwan, Thailand, India
Shanghai Chest Hospital
Chang Gung Memorial Hospital; Tianjin Medical University Cancer Institute and... and other collaborators

Unknown

Pre-Surgery If Needed for Oesophageal Cancer (preSINO)

Esophageal Cancer

China, Hong Kong, Taiwan
National Cancer Institute (NCI)

Active, not recruiting

Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma

Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma | Recurrent Nasopharyngeal Undifferentiated Carcinoma | Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Adult Nasal Type Extranodal NK/T-Cell Lymphoma | Stage IV Nasopharyngeal Undifferentiated Carcinoma...

United States, Singapore, China, Japan
Bayer

Terminated

A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

China, Taiwan, Singapore, Thailand, Korea, Republic of, India
Pfizer

Completed

A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients

NSCLC (Non-small Cell Lung Cancer)

Hong Kong, China, Taiwan, Malaysia, Thailand
Boehringer Ingelheim

Active, not recruiting

A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

Neoplasms | Non-squamous, Non-Small-Cell Lung Cancer

United States, Spain, Korea, Republic of, France, Hong Kong, United Kingdom, Germany, Australia, Taiwan, Poland, Russian Federation, Ukraine
Chinese University of Hong Kong
Prince of Wales Hospital, Shatin, Hong Kong

Completed

Multiplex PCR -Microarray-based Assay in the Detection of Mycobacterium

Tuberculosis | Non-Tuberculous Mycobacterial Pneumonia

Hong Kong
Shanghai EpimAb Biotherapeutics Co., Ltd.
Covance

Recruiting

A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors

Neoplasms | Neoplasm Metastasis | Non-Small-Cell Lung Cancer

United States, China
Takeda

Completed

A Chart Review Study of Adults With Advanced NSCLC (EXTRACT)

Non-small Cell Lung Cancer (NSCLC)

Hong Kong, France, Canada
Hong Kong Sanatorium & Hospital
Chinese University of Hong Kong; Stanford University

Completed

Mast Cell Activation Test in Allergic Disease

Asthma | Eczema | Food Allergy | Mastocytosis | Chronic Idiopathic Urticaria | Anaphylaxis | Mast Cell Activation Syndrome

Hong Kong
AstraZeneca

Completed

Phase II AZD9291 Open Label Study in NSCLC After Previous EGFR TKI Therapy in EGFR and T790M Mutation Positive Tumours (AURA2)

Non Small Cell Lung Cancer

Italy, United States, Canada, Korea, Republic of, Japan, Taiwan, Hong Kong, Spain
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Singapore, Hong Kong, Canada
Novartis Pharmaceuticals

Terminated

Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50%

Non-small Cell Lung Cancer (NSCLC)

Japan, Germany, Spain, Italy, France, Thailand, Belgium, Netherlands, India, Malaysia, Taiwan, Australia, Canada, Czechia, Greece, Hong Kong
Merck KGaA, Darmstadt, Germany

Terminated

Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population (INSPIRE)

Non-Small Cell Lung Cancer

Korea, Republic of, Taiwan, Singapore, China, Hong Kong
Novartis Pharmaceuticals

Terminated

An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations

Advanced Non Small Cell Lung Cancer (NSCLC)

France, Italy, Taiwan, Spain, Netherlands, Japan, Hong Kong, Korea, Republic of, Norway, United States, United Kingdom, Poland
Pfizer

Completed

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Non-small Cell Lung Cancer With EGFR-Activating Mutations

Italy, Poland, China, Hong Kong, Spain, Korea, Republic of, Japan
Boehringer Ingelheim

Completed

Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation

Carcinoma, Non-Small-Cell Lung

Hong Kong, China, Taiwan, Singapore, India
AVEO Pharmaceuticals, Inc.
Biodesix, Inc.

Terminated

A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label (FOCAL)

Non-small Cell Lung Cancer

Korea, Republic of, United States, Australia, Taiwan, Singapore, Hong Kong, Italy
Li Zhang, MD

Recruiting

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

China
Qianfoshan Hospital

Recruiting

Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC

Extensive Small Cell Lung Cancer

China
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (CheckMate722)

Non-Small-Cell Lung Carcinoma

United States, China, Taiwan, Spain, Korea, Republic of, France, Canada, Hong Kong, Japan, Singapore
AstraZeneca

Recruiting

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC) (TARGET)

Stage II-IIIB Non-small Cell Lung Carcinoma

Spain, Korea, Republic of, Philippines, Italy, United States, Malaysia, Taiwan, Thailand, Hong Kong, United Kingdom, Singapore
Novartis Pharmaceuticals

Completed

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Non-Small Cell Lung Cancer

China
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
Merck KGaA, Darmstadt, Germany

Completed

Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) (FLEX)

Non Small Cell Lung Cancer (NSCLC)

Sweden, Australia, Brazil, Bulgaria, Czech Republic, France, Italy, Korea, Republic of, Mexico, Russian Federation, Spain, Turkey, United Kingdom, Germany, Poland, Ukraine, Argentina, Austria, Hungary, Netherlands, Slovakia, Taiwan, Chil... and more
BioAtla, Inc.

Recruiting

CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC

Non-Small-Cell Lung Cancer

United States, Hong Kong, Taiwan, Spain, Greece, Germany, Italy, Poland
AstraZeneca

Completed

A Study of IRESSA Treatment Beyond Progression in Addition to Chemotherapy Versus Chemotherapy Alone (IMPRESS)

Non-Small Cell Lung Cancer

Italy, Spain, France, Korea, Republic of, Hungary, Japan, China, Taiwan, Hong Kong, Germany, Russian Federation
Eisai Inc.

Completed

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Hong Kong, Taiwan, Korea, Republic of, Singapore, Thailand, Malaysia
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
Novartis Pharmaceuticals

Completed

An East Asian Study of LDE225

Medulloblastoma | Basal Cell Carcinoma | Advanced Solid Tumor Cancers

Taiwan, Hong Kong, Japan
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer (ARC-10)

Lung Cancer | Non Small Cell Lung Cancer | Squamous Non Small Cell Lung Cancer | Nonsquamous Non Small Cell Lung Cancer

Philippines, Thailand, France, Korea, Republic of, Hong Kong, United States, Turkey, Malaysia, Taiwan, Brazil, Serbia, Greece, Slovakia, Peru, South Africa, Mexico, Vietnam, Bangladesh
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

Israel, Taiwan, United States, Australia, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia
Daiichi Sankyo

Recruiting

HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer (NSCLC)

United States, Korea, Republic of, Spain, Japan, Netherlands, Taiwan
Sun Yat-sen University

Recruiting

Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in the Treatment of Small Cell Lung Cancer

Small Cell Lung Carcinoma

China
Hoffmann-La Roche

Completed

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Non-small Cell Lung Cancer

Belgium, Italy, Portugal, Spain, Germany, Turkey, France, Hong Kong, Korea, Republic of, Poland, Russian Federation, Hungary, Norway, Bulgaria, Slovakia
University of Medicine and Dentistry of New Jersey
National Cancer Institute (NCI); Aventis Pharmaceuticals

Terminated

Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
MedImmune LLC

Completed

Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC (COAST)

Stage III Non-small Cell Lung Cancer | Unresectable

United States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7)

ALK-positive Non-small Cell Lung Cancer

United States, France, Italy, United Kingdom, Taiwan, Turkey, Belgium, Germany, Canada, Singapore, Spain, Korea, Republic of, Netherlands, Russian Federation, Brazil, Hong Kong, Australia

Clinical Trials on Carcinoma, Non-Small-Cell Lung in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations